Volume 10, Issue 1 (6-2023)                   vacres 2023, 10(1): 11-17 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sabzi S, Badmasti F, Noori Goodarzi N, Habibi M, Shahbazi S, Asadi Karam M R et al . In silico Evaluation, Cloning, and Expression of Omp22 as a Promising Vaccine Candidate against Acinetobacter baumannii. vacres 2023; 10 (1) :11-17
URL: http://vacres.pasteur.ac.ir/article-1-324-en.html
National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (803 Views)
Introduction: There is currently no approved vaccine available for Acinetobacter baumannii, an important agent of nosocomial infections. Recently, Omp22 from A. baumannii has been identified as a vaccine candidate that stimulates effective immune responses in mice. However, limited data is available about this protein. This study aimed to comprehensively analyze the immunoinformatic properties of Omp22 and its expression in vitro. Methods: The protein sequence of Omp22 was scanned for subcellular localization, antigenicity, allergenicity, homology to human proteome, physiochemical characteristics, linear and conformational B-cell epitopes, MHC binding sites, tertiary structure prediction, and molecular dockings. Additionally, the gene encoding omp22 was cloned into the pET-28a (+) vector and the expression level was optimized. Results: Omp22 (22.48 kDa, pI of 9.30) belongs to the outer membrane proteins superfamily without transmembrane helices. Omp22 was predicted to be a non-allergenic antigen with appropriate stability. Two linear B-cell epitopes were identified, as well as 108 MHC-I and 50 MHC-II binding sites. Three conformational B-cell epitopes were identified through 3D structure prediction, and molecular docking analysis showed desirable interactions in the docked complexes. The optimized expression of the recombinant Omp22 was successfully achieved. Conclusion: This study represents a significant step towards developing an Omp22-based vaccine candidate against A. baumannii. However, further experimental analyses are still needed
Full-Text [PDF 797 kb]   (295 Downloads)    
Type of Study: Original article | Subject: Vaccine development, efficacy and safety evaluation
Received: 2023/06/28

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.